PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA
Abstract
Authors
JC Sambrook AR Levy KM Johnston NJ Ricard C Bourgault BM Donato SJ Hotte MR Chasen A Briggs